PHOENIX, Ariz., Dec. 02, 2015 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (“Insys”) (INSY) today announced the presenting speakers for its Investor Day to be held on Thursday, December 3, 2015 from 8:30 a.m. to 11:30 a.m. EST at The Pierre Hotel in NYC.
The Insys executive management team will be joined by several healthcare Key Opinion Leaders. Scientific presentations will be given by:
Dennis J. Dlugos, MD, MSCE
Professor of Neurology and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania; Director, Pediatric Regional Epilepsy Program at the Children’s Hospital of Philadelphia (CHOP)
Jeff Gudin, MD
Director, Pain and Palliative Care at Englewood Hospital and Medical Center, New Jersey; Clinical Instructor, Anesthesiology at the Icahn School of Medicine at Mt. Sinai
Douglas Glenn Brust, MD, PhD
Chief of Staff, Lee Memorial Health System, Fort Myers, Florida
“We are honored to have these distinguished speakers and practitioners share their insights at the Insys Investor Day,” stated Dr. John Kapoor, Chairman, President and Chief Executive Officer. “We look forward to updating investors on our key development programs including our sublingual spray technology; Syndros® (dronabinol oral solution); pharmaceutical cannabinoids; and Subsys®. We are pleased to have these candidates in development to meet underserved medical needs in oncology, epilepsy, CINV, and pain amongst other areas.”
The Insys Investor Day is by invitation only for analysts and institutional investors. An RSVP to Lisa Wilson via email at firstname.lastname@example.org is required to attend.
A live webcast of the Insys Investor Day will be available on the Insys website through the “News and Events” page at www.insysrx.com.
A replay of the Insys Investor Day webcast will be available approximately two hours following the completion of the event at the aforementioned URL. The archived webcast will be available for 90 days.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product: Subsys® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Syndros® (dronabinol oral solution), a proprietary, orally administered formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.
Subsys® and Syndros® are registered trademarks of Insys Therapeutics, Inc.
Lisa M. Wilson
In-Site Communications, Inc.